title: Degranulation of mast cells located in median eminence in response to compound 48/80 evokes adrenocortical secretion via histamine and CRF in dogs.
abstract: The effect of intracerebroventricular infusion of compound 48/80 (C48/80), a mast cell secretagogue, on adrenal cortisol secretion was investigated in dogs under pentobarbital sodium anesthesia. A marked increase in adrenal cortisol secretion was elicited by C48/80 along with a concomitant increase in the plasma levels of cortisol and immunoreactive ACTH, but neither arterial blood pressure and heart rate nor the plasma histamine level altered significantly. Pretreatment with either anti-CRF antiserum or pyrilamine maleate (H(1) histamine-receptor antagonist) significantly attenuated the C48/80-evoked increase in cortisol secretion, but pretreatment with metiamide (H(2)-receptor antagonist) significantly potentiated it. Significant attenuation of the C48/80-evoked increase in cortisol also occurred in dogs given ketotifen, a mast cell stabilizing drug, before pharmacologic challenge. In the pars tuberalis and median eminence (ME), mast cells were highly concentrated in close association with the primary plexus of the hypophysial portal system. Degranulated mast cells were extensively found in the ME of C48/80-treated animals. These results suggest that mast cells located in these regions liberated histamine within the brain as a result of degranulation induced by C48/80 and that this led to activation of the hypothalamic-pituitary-adrenocortical axis.
authors.affiliation: Dept. of Physiology, Nagasaki Univ. School of Medicine, Nagasaki 852-8523, Japan. matu-itu@net.nagasaki-u.ac.jp
authors.forename: Itsuro
authors.initials: I
authors.lastname: Matsumoto
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Inoue
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Tsuchiya
authors.forename: Toshio
authors.initials: T
authors.lastname: Shimada
authors.forename: Tadaomi
authors.initials: T
authors.lastname: Aikawa
mesh_terms: D000302:Adrenal Cortex / Q000187:drug effects / Q000378:metabolism*; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000818:Animals; D015550:Cell Degranulation / Q000187:drug effects*; D002855:Chromatography, Thin Layer; D003346:Corticotropin-Releasing Hormone / Q000502:physiology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006632:Histamine / Q000097:blood / Q000502:physiology*; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D006854:Hydrocortisone / Q000097:blood / Q000378:metabolism; D007276:Injections, Intraventricular; D007665:Ketotifen / Q000494:pharmacology; D008297:Male; D008473:Median Eminence / Q000166:cytology* / Q000187:drug effects*; D008785:Metiamide / Q000494:pharmacology; D011738:Pyrilamine / Q000494:pharmacology; D013152:Splanchnic Circulation / Q000502:physiology; D003189:p-Methoxy-N-methylphenethylamine / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*
chemical_list: D006634:Histamine H1 Antagonists; D006635:Histamine H2 Antagonists; D008785:Metiamide; D003189:p-Methoxy-N-methylphenethylamine; D006632:Histamine; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D011738:Pyrilamine; D006854:Hydrocortisone; D007665:Ketotifen; D004837:Epinephrine